Synergistic effects of various Her inhibitors in combination with IGF-1R, C-MET and Src targeting agents in breast cancer cell lines

Overexpression of HER2 has been reported in around 25% of human breast cancers. Despite recent advances in HER2 targeted therapy, many patients still experience primary and secondary resistance to such treatments, the mechanisms for which are poorly understood. Here, we investigated the sensitivity...

Descripción completa

Detalles Bibliográficos
Autores principales: Stanley, Aryan, Ashrafi, G. Hossein, Seddon, Alan M., Modjtahedi, Helmout
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Nature Publishing Group UK 2017
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5479850/
https://www.ncbi.nlm.nih.gov/pubmed/28638122
http://dx.doi.org/10.1038/s41598-017-04301-8

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5479850/
https://www.ncbi.nlm.nih.gov/pubmed/28638122
http://dx.doi.org/10.1038/s41598-017-04301-8

Ejemplares similares